IMMP - Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

• Immutep ( NASDAQ: IMMP ) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor.
• The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual property related to combined therapeutic preparations consisting of  immunotherapy candidate eftilagimod alpha and an anti-PD-( L )1 antibody, the company said in an Aug. 30 press release.
• The company added that the claims are also directed to related methods of use in treating cancer and infection.
• "This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months," said Immutep CEO Marc Voigt.
• The patent is expected to expire Jan. 8, 2036.

For further details see: